trial · primary record
Methylprednisolone (MP)
Antibody-mediated Rejection
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2028-06-30 |
| Primary endpoint | Incidence of CTCAE v6.0 grade ≥ 3 adverse events (AEs) during the Phase A (0-24 weeks) follow-up period. |
| Registry ID | NCT07902609 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:31:47.847Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07902609
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- METHYLPREDNISOLONE · approval
- Methylprednisolone · compound